WO2023078333A1 - 一种取代的苯丙酸衍生物及其用途一种取代的苯丙酸衍生物及其用途 - Google Patents
一种取代的苯丙酸衍生物及其用途一种取代的苯丙酸衍生物及其用途 Download PDFInfo
- Publication number
- WO2023078333A1 WO2023078333A1 PCT/CN2022/129479 CN2022129479W WO2023078333A1 WO 2023078333 A1 WO2023078333 A1 WO 2023078333A1 CN 2022129479 W CN2022129479 W CN 2022129479W WO 2023078333 A1 WO2023078333 A1 WO 2023078333A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- compound
- pharmaceutically acceptable
- acceptable salt
- independently selected
- alkyl
- Prior art date
Links
- YPGCWEMNNLXISK-UHFFFAOYSA-N hydratropic acid Chemical class OC(=O)C(C)C1=CC=CC=C1 YPGCWEMNNLXISK-UHFFFAOYSA-N 0.000 title abstract description 3
- 150000001875 compounds Chemical class 0.000 claims abstract description 148
- 150000003839 salts Chemical class 0.000 claims abstract description 88
- 238000002360 preparation method Methods 0.000 claims abstract description 42
- 239000003814 drug Substances 0.000 claims abstract description 16
- 208000024172 Cardiovascular disease Diseases 0.000 claims abstract description 7
- 125000000217 alkyl group Chemical group 0.000 claims description 61
- 229910052736 halogen Inorganic materials 0.000 claims description 46
- 150000002367 halogens Chemical class 0.000 claims description 46
- 229910052739 hydrogen Inorganic materials 0.000 claims description 44
- 239000001257 hydrogen Substances 0.000 claims description 44
- 229910052805 deuterium Inorganic materials 0.000 claims description 37
- YZCKVEUIGOORGS-OUBTZVSYSA-N Deuterium Chemical compound [2H] YZCKVEUIGOORGS-OUBTZVSYSA-N 0.000 claims description 36
- 125000003545 alkoxy group Chemical group 0.000 claims description 35
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 34
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 27
- 125000004093 cyano group Chemical group *C#N 0.000 claims description 26
- 239000008194 pharmaceutical composition Substances 0.000 claims description 23
- 238000006467 substitution reaction Methods 0.000 claims description 19
- 150000002431 hydrogen Chemical class 0.000 claims description 16
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 16
- 239000000460 chlorine Substances 0.000 claims description 15
- 238000000034 method Methods 0.000 claims description 15
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 claims description 12
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 claims description 12
- 229910052801 chlorine Inorganic materials 0.000 claims description 12
- 229910052731 fluorine Inorganic materials 0.000 claims description 12
- 239000011737 fluorine Substances 0.000 claims description 12
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 10
- 201000010099 disease Diseases 0.000 claims description 8
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 8
- 125000001424 substituent group Chemical group 0.000 claims description 8
- 230000000155 isotopic effect Effects 0.000 claims description 7
- 230000036470 plasma concentration Effects 0.000 claims description 6
- 238000011282 treatment Methods 0.000 claims description 5
- 230000002265 prevention Effects 0.000 claims description 3
- 229940079593 drug Drugs 0.000 abstract description 10
- 238000006243 chemical reaction Methods 0.000 description 69
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 63
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 62
- 239000000243 solution Substances 0.000 description 57
- -1 cholesteryl ester Chemical class 0.000 description 40
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 32
- 238000004949 mass spectrometry Methods 0.000 description 31
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 27
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 26
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 24
- 102100040214 Apolipoprotein(a) Human genes 0.000 description 23
- 238000004895 liquid chromatography mass spectrometry Methods 0.000 description 22
- 239000012071 phase Substances 0.000 description 21
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 19
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 19
- LPQZERIRKRYGGM-UHFFFAOYSA-N tert-butyl pyrrolidine-1-carboxylate Chemical compound CC(C)(C)OC(=O)N1CCCC1 LPQZERIRKRYGGM-UHFFFAOYSA-N 0.000 description 19
- 239000012043 crude product Substances 0.000 description 18
- 238000003818 flash chromatography Methods 0.000 description 18
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 17
- 210000002381 plasma Anatomy 0.000 description 16
- 101710115418 Apolipoprotein(a) Proteins 0.000 description 15
- 239000000706 filtrate Substances 0.000 description 15
- 125000000592 heterocycloalkyl group Chemical group 0.000 description 15
- 239000000203 mixture Substances 0.000 description 15
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 15
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 14
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 14
- XBDQKXXYIPTUBI-UHFFFAOYSA-N dimethylselenoniopropionate Natural products CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 description 13
- 229910052757 nitrogen Inorganic materials 0.000 description 13
- IUVKMZGDUIUOCP-BTNSXGMBSA-N quinbolone Chemical compound O([C@H]1CC[C@H]2[C@H]3[C@@H]([C@]4(C=CC(=O)C=C4CC3)C)CC[C@@]21C)C1=CCCC1 IUVKMZGDUIUOCP-BTNSXGMBSA-N 0.000 description 13
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 13
- 241000282567 Macaca fascicularis Species 0.000 description 12
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 12
- 238000012360 testing method Methods 0.000 description 12
- 238000005481 NMR spectroscopy Methods 0.000 description 11
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 11
- 229960000583 acetic acid Drugs 0.000 description 11
- 230000002829 reductive effect Effects 0.000 description 11
- 239000000741 silica gel Substances 0.000 description 11
- 229910002027 silica gel Inorganic materials 0.000 description 11
- LMBFAGIMSUYTBN-MPZNNTNKSA-N teixobactin Chemical compound C([C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H](CCC(N)=O)C(=O)N[C@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H]1C(N[C@@H](C)C(=O)N[C@@H](C[C@@H]2NC(=N)NC2)C(=O)N[C@H](C(=O)O[C@H]1C)[C@@H](C)CC)=O)NC)C1=CC=CC=C1 LMBFAGIMSUYTBN-MPZNNTNKSA-N 0.000 description 11
- 241000282472 Canis lupus familiaris Species 0.000 description 10
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 10
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 10
- 239000012074 organic phase Substances 0.000 description 10
- 241000699670 Mus sp. Species 0.000 description 9
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 9
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 9
- 210000004369 blood Anatomy 0.000 description 9
- 239000008280 blood Substances 0.000 description 9
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 8
- 238000000746 purification Methods 0.000 description 8
- 238000003756 stirring Methods 0.000 description 8
- 239000000126 substance Substances 0.000 description 8
- AQRLNPVMDITEJU-UHFFFAOYSA-N triethylsilane Chemical compound CC[SiH](CC)CC AQRLNPVMDITEJU-UHFFFAOYSA-N 0.000 description 8
- WORJRXHJTUTINR-UHFFFAOYSA-N 1,4-dioxane;hydron;chloride Chemical compound Cl.C1COCCO1 WORJRXHJTUTINR-UHFFFAOYSA-N 0.000 description 7
- 108010012927 Apoprotein(a) Proteins 0.000 description 7
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical class [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 7
- 125000004432 carbon atom Chemical group C* 0.000 description 7
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 description 7
- 238000002474 experimental method Methods 0.000 description 7
- 239000003208 petroleum Substances 0.000 description 7
- 235000019260 propionic acid Nutrition 0.000 description 7
- 239000013558 reference substance Substances 0.000 description 7
- 239000011734 sodium Substances 0.000 description 7
- BEOOHQFXGBMRKU-UHFFFAOYSA-N sodium cyanoborohydride Chemical compound [Na+].[B-]C#N BEOOHQFXGBMRKU-UHFFFAOYSA-N 0.000 description 7
- 125000004213 tert-butoxy group Chemical group [H]C([H])([H])C(O*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 7
- 238000004809 thin layer chromatography Methods 0.000 description 7
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 6
- WMFOQBRAJBCJND-UHFFFAOYSA-M Lithium hydroxide Chemical compound [Li+].[OH-] WMFOQBRAJBCJND-UHFFFAOYSA-M 0.000 description 6
- BZLVMXJERCGZMT-UHFFFAOYSA-N Methyl tert-butyl ether Chemical compound COC(C)(C)C BZLVMXJERCGZMT-UHFFFAOYSA-N 0.000 description 6
- 238000004458 analytical method Methods 0.000 description 6
- 238000004440 column chromatography Methods 0.000 description 6
- 150000002148 esters Chemical class 0.000 description 6
- 238000001294 liquid chromatography-tandem mass spectrometry Methods 0.000 description 6
- DUWWHGPELOTTOE-UHFFFAOYSA-N n-(5-chloro-2,4-dimethoxyphenyl)-3-oxobutanamide Chemical compound COC1=CC(OC)=C(NC(=O)CC(C)=O)C=C1Cl DUWWHGPELOTTOE-UHFFFAOYSA-N 0.000 description 6
- 230000002441 reversible effect Effects 0.000 description 6
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 5
- 125000004575 3-pyrrolidinyl group Chemical group [H]N1C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 5
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 5
- 102000018616 Apolipoproteins B Human genes 0.000 description 5
- 108010027006 Apolipoproteins B Proteins 0.000 description 5
- MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 5
- KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 5
- 239000003795 chemical substances by application Substances 0.000 description 5
- 235000019253 formic acid Nutrition 0.000 description 5
- 239000007788 liquid Substances 0.000 description 5
- FESDUDPSRMWIDL-UHFFFAOYSA-N tert-butyl n,n'-di(propan-2-yl)carbamimidate Chemical compound CC(C)NC(OC(C)(C)C)=NC(C)C FESDUDPSRMWIDL-UHFFFAOYSA-N 0.000 description 5
- LMPIFZSJKLLOLM-UHFFFAOYSA-N 1,1,3-trioxo-1,2-benzothiazole-2-carbaldehyde Chemical compound C1=CC=C2S(=O)(=O)N(C=O)C(=O)C2=C1 LMPIFZSJKLLOLM-UHFFFAOYSA-N 0.000 description 4
- BCJVBDBJSMFBRW-UHFFFAOYSA-N 4-diphenylphosphanylbutyl(diphenyl)phosphane Chemical compound C=1C=CC=CC=1P(C=1C=CC=CC=1)CCCCP(C=1C=CC=CC=1)C1=CC=CC=C1 BCJVBDBJSMFBRW-UHFFFAOYSA-N 0.000 description 4
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 4
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 4
- 230000037396 body weight Effects 0.000 description 4
- 239000003153 chemical reaction reagent Substances 0.000 description 4
- 239000012141 concentrate Substances 0.000 description 4
- 238000001514 detection method Methods 0.000 description 4
- 230000000694 effects Effects 0.000 description 4
- 125000004435 hydrogen atom Chemical group [H]* 0.000 description 4
- KWGKDLIKAYFUFQ-UHFFFAOYSA-M lithium chloride Chemical compound [Li+].[Cl-] KWGKDLIKAYFUFQ-UHFFFAOYSA-M 0.000 description 4
- YJVFFLUZDVXJQI-UHFFFAOYSA-L palladium(ii) acetate Chemical compound [Pd+2].CC([O-])=O.CC([O-])=O YJVFFLUZDVXJQI-UHFFFAOYSA-L 0.000 description 4
- VLTRZXGMWDSKGL-UHFFFAOYSA-N perchloric acid Chemical compound OCl(=O)(=O)=O VLTRZXGMWDSKGL-UHFFFAOYSA-N 0.000 description 4
- 238000010791 quenching Methods 0.000 description 4
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical class O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 4
- 239000007787 solid Substances 0.000 description 4
- 239000002904 solvent Substances 0.000 description 4
- 239000006228 supernatant Substances 0.000 description 4
- 239000003643 water by type Substances 0.000 description 4
- HBENZIXOGRCSQN-VQWWACLZSA-N (1S,2S,6R,14R,15R,16R)-5-(cyclopropylmethyl)-16-[(2S)-2-hydroxy-3,3-dimethylpentan-2-yl]-15-methoxy-13-oxa-5-azahexacyclo[13.2.2.12,8.01,6.02,14.012,20]icosa-8(20),9,11-trien-11-ol Chemical compound N1([C@@H]2CC=3C4=C(C(=CC=3)O)O[C@H]3[C@@]5(OC)CC[C@@]2([C@@]43CC1)C[C@@H]5[C@](C)(O)C(C)(C)CC)CC1CC1 HBENZIXOGRCSQN-VQWWACLZSA-N 0.000 description 3
- FANCTJAFZSYTIS-IQUVVAJASA-N (1r,3s,5z)-5-[(2e)-2-[(1r,3as,7ar)-7a-methyl-1-[(2r)-4-(phenylsulfonimidoyl)butan-2-yl]-2,3,3a,5,6,7-hexahydro-1h-inden-4-ylidene]ethylidene]-4-methylidenecyclohexane-1,3-diol Chemical compound C([C@@H](C)[C@@H]1[C@]2(CCCC(/[C@@H]2CC1)=C\C=C\1C([C@@H](O)C[C@H](O)C/1)=C)C)CS(=N)(=O)C1=CC=CC=C1 FANCTJAFZSYTIS-IQUVVAJASA-N 0.000 description 3
- VIMMECPCYZXUCI-MIMFYIINSA-N (4s,6r)-6-[(1e)-4,4-bis(4-fluorophenyl)-3-(1-methyltetrazol-5-yl)buta-1,3-dienyl]-4-hydroxyoxan-2-one Chemical compound CN1N=NN=C1C(\C=C\[C@@H]1OC(=O)C[C@@H](O)C1)=C(C=1C=CC(F)=CC=1)C1=CC=C(F)C=C1 VIMMECPCYZXUCI-MIMFYIINSA-N 0.000 description 3
- VAVHMEQFYYBAPR-ITWZMISCSA-N (e,3r,5s)-7-[4-(4-fluorophenyl)-1-phenyl-2-propan-2-ylpyrrol-3-yl]-3,5-dihydroxyhept-6-enoic acid Chemical compound CC(C)C1=C(\C=C\[C@@H](O)C[C@@H](O)CC(O)=O)C(C=2C=CC(F)=CC=2)=CN1C1=CC=CC=C1 VAVHMEQFYYBAPR-ITWZMISCSA-N 0.000 description 3
- JWUJQDFVADABEY-UHFFFAOYSA-N 2-methyltetrahydrofuran Chemical compound CC1CCCO1 JWUJQDFVADABEY-UHFFFAOYSA-N 0.000 description 3
- NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonia chloride Chemical class [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 3
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 3
- 101000889990 Homo sapiens Apolipoprotein(a) Proteins 0.000 description 3
- 241001465754 Metazoa Species 0.000 description 3
- 229940125907 SJ995973 Drugs 0.000 description 3
- 238000010521 absorption reaction Methods 0.000 description 3
- 239000002253 acid Substances 0.000 description 3
- 239000008346 aqueous phase Substances 0.000 description 3
- 239000007864 aqueous solution Substances 0.000 description 3
- 239000012298 atmosphere Substances 0.000 description 3
- 125000004429 atom Chemical group 0.000 description 3
- CBHOOMGKXCMKIR-UHFFFAOYSA-N azane;methanol Chemical compound N.OC CBHOOMGKXCMKIR-UHFFFAOYSA-N 0.000 description 3
- 230000027455 binding Effects 0.000 description 3
- 238000007796 conventional method Methods 0.000 description 3
- 238000001816 cooling Methods 0.000 description 3
- 238000010790 dilution Methods 0.000 description 3
- 239000012895 dilution Substances 0.000 description 3
- BYRPTKZOXNFFDB-UHFFFAOYSA-N lithium;bis(trimethylsilyl)azanide;oxolane Chemical compound [Li+].C1CCOC1.C[Si](C)(C)[N-][Si](C)(C)C BYRPTKZOXNFFDB-UHFFFAOYSA-N 0.000 description 3
- 239000002808 molecular sieve Substances 0.000 description 3
- XZMHJYWMCRQSSI-UHFFFAOYSA-N n-[5-[2-(3-acetylanilino)-1,3-thiazol-4-yl]-4-methyl-1,3-thiazol-2-yl]benzamide Chemical compound CC(=O)C1=CC=CC(NC=2SC=C(N=2)C2=C(N=C(NC(=O)C=3C=CC=CC=3)S2)C)=C1 XZMHJYWMCRQSSI-UHFFFAOYSA-N 0.000 description 3
- 239000012299 nitrogen atmosphere Substances 0.000 description 3
- 125000004433 nitrogen atom Chemical group N* 0.000 description 3
- 239000000047 product Substances 0.000 description 3
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 3
- 239000002994 raw material Substances 0.000 description 3
- RWWYLEGWBNMMLJ-YSOARWBDSA-N remdesivir Chemical compound NC1=NC=NN2C1=CC=C2[C@]1([C@@H]([C@@H]([C@H](O1)CO[P@](=O)(OC1=CC=CC=C1)N[C@H](C(=O)OCC(CC)CC)C)O)O)C#N RWWYLEGWBNMMLJ-YSOARWBDSA-N 0.000 description 3
- 229920006395 saturated elastomer Polymers 0.000 description 3
- URGAHOPLAPQHLN-UHFFFAOYSA-N sodium aluminosilicate Chemical compound [Na+].[Al+3].[O-][Si]([O-])=O.[O-][Si]([O-])=O URGAHOPLAPQHLN-UHFFFAOYSA-N 0.000 description 3
- 239000007858 starting material Substances 0.000 description 3
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 2
- KAFZOLYKKCWUBI-HPMAGDRPSA-N (2s)-2-[[(2s)-2-[[(2s)-1-[(2s)-3-amino-2-[[(2s)-2-[[(2s)-2-(3-cyclohexylpropanoylamino)-4-methylpentanoyl]amino]-5-methylhexanoyl]amino]propanoyl]pyrrolidine-2-carbonyl]amino]-5-(diaminomethylideneamino)pentanoyl]amino]butanediamide Chemical compound N([C@@H](CC(C)C)C(=O)N[C@@H](CCC(C)C)C(=O)N[C@@H](CN)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](CC(N)=O)C(N)=O)C(=O)CCC1CCCCC1 KAFZOLYKKCWUBI-HPMAGDRPSA-N 0.000 description 2
- PHDIJLFSKNMCMI-ITGJKDDRSA-N (3R,4S,5R,6R)-6-(hydroxymethyl)-4-(8-quinolin-6-yloxyoctoxy)oxane-2,3,5-triol Chemical compound OC[C@@H]1[C@H]([C@@H]([C@H](C(O1)O)O)OCCCCCCCCOC=1C=C2C=CC=NC2=CC=1)O PHDIJLFSKNMCMI-ITGJKDDRSA-N 0.000 description 2
- FOLCUFKJHSQMEL-BIXPGCQOSA-N (4-butylcyclohexyl) N-[(2S)-4-methyl-1-oxo-1-[[(2S)-1-oxo-3-[(3S)-2-oxopyrrolidin-3-yl]propan-2-yl]amino]pentan-2-yl]carbamate Chemical compound CCCCC1CCC(CC1)OC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C[C@@H]2CCNC2=O)C=O FOLCUFKJHSQMEL-BIXPGCQOSA-N 0.000 description 2
- VUDZSIYXZUYWSC-DBRKOABJSA-N (4r)-1-[(2r,4r,5r)-3,3-difluoro-4-hydroxy-5-(hydroxymethyl)oxolan-2-yl]-4-hydroxy-1,3-diazinan-2-one Chemical compound FC1(F)[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)N[C@H](O)CC1 VUDZSIYXZUYWSC-DBRKOABJSA-N 0.000 description 2
- QBTROWHSMGZXCV-RQURQNPSSA-N (6r,7r)-1-[(4s,5r)-4-acetyloxy-5-methyl-3-methylidene-6-phenylhexyl]-4,7-dihydroxy-6-(11-phenoxyundecoxy)-2,8-dioxabicyclo[3.2.1]octane-3,4,5-tricarboxylic acid Chemical compound C([C@@H](C)[C@H](OC(C)=O)C(=C)CCC12[C@@H]([C@@H](OCCCCCCCCCCCOC=3C=CC=CC=3)C(O1)(C(O)=O)C(O)(C(O2)C(O)=O)C(O)=O)O)C1=CC=CC=C1 QBTROWHSMGZXCV-RQURQNPSSA-N 0.000 description 2
- UXKLQDCALAWFIU-VKNDCNMPSA-N (6r,7r)-1-[(4s,5r)-4-acetyloxy-5-methyl-3-methylidene-6-phenylhexyl]-4,7-dihydroxy-6-tetradecoxy-2,8-dioxabicyclo[3.2.1]octane-3,4,5-tricarboxylic acid Chemical compound C([C@@H](C)[C@H](OC(C)=O)C(=C)CCC12[C@H](O)[C@H](C(O2)(C(O)=O)C(O)(C(O1)C(O)=O)C(O)=O)OCCCCCCCCCCCCCC)C1=CC=CC=C1 UXKLQDCALAWFIU-VKNDCNMPSA-N 0.000 description 2
- VGNCBRNRHXEODV-XXVHXNRLSA-N (6r,7r)-1-[(4s,5r)-4-acetyloxy-5-methyl-3-methylidene-6-phenylhexyl]-6-dodecoxy-4,7-dihydroxy-2,8-dioxabicyclo[3.2.1]octane-3,4,5-tricarboxylic acid Chemical compound C([C@@H](C)[C@H](OC(C)=O)C(=C)CCC12[C@H](O)[C@H](C(O2)(C(O)=O)C(O)(C(O1)C(O)=O)C(O)=O)OCCCCCCCCCCCC)C1=CC=CC=C1 VGNCBRNRHXEODV-XXVHXNRLSA-N 0.000 description 2
- QRDAPCMJAOQZSU-KQQUZDAGSA-N (e)-3-[4-[(e)-3-(3-fluorophenyl)-3-oxoprop-1-enyl]-1-methylpyrrol-2-yl]-n-hydroxyprop-2-enamide Chemical compound C1=C(\C=C\C(=O)NO)N(C)C=C1\C=C\C(=O)C1=CC=CC(F)=C1 QRDAPCMJAOQZSU-KQQUZDAGSA-N 0.000 description 2
- IGVKWAAPMVVTFX-BUHFOSPRSA-N (e)-octadec-5-en-7,9-diynoic acid Chemical compound CCCCCCCCC#CC#C\C=C\CCCC(O)=O IGVKWAAPMVVTFX-BUHFOSPRSA-N 0.000 description 2
- JNPGUXGVLNJQSQ-BGGMYYEUSA-M (e,3r,5s)-7-[4-(4-fluorophenyl)-1,2-di(propan-2-yl)pyrrol-3-yl]-3,5-dihydroxyhept-6-enoate Chemical compound CC(C)N1C(C(C)C)=C(\C=C\[C@@H](O)C[C@@H](O)CC([O-])=O)C(C=2C=CC(F)=CC=2)=C1 JNPGUXGVLNJQSQ-BGGMYYEUSA-M 0.000 description 2
- JVSFQJZRHXAUGT-UHFFFAOYSA-N 2,2-dimethylpropanoyl chloride Chemical compound CC(C)(C)C(Cl)=O JVSFQJZRHXAUGT-UHFFFAOYSA-N 0.000 description 2
- MWDVCHRYCKXEBY-LBPRGKRZSA-N 3-chloro-n-[2-oxo-2-[[(1s)-1-phenylethyl]amino]ethyl]benzamide Chemical compound N([C@@H](C)C=1C=CC=CC=1)C(=O)CNC(=O)C1=CC=CC(Cl)=C1 MWDVCHRYCKXEBY-LBPRGKRZSA-N 0.000 description 2
- HIHOEGPXVVKJPP-JTQLQIEISA-N 5-fluoro-2-[[(1s)-1-(5-fluoropyridin-2-yl)ethyl]amino]-6-[(5-methyl-1h-pyrazol-3-yl)amino]pyridine-3-carbonitrile Chemical compound N([C@@H](C)C=1N=CC(F)=CC=1)C(C(=CC=1F)C#N)=NC=1NC=1C=C(C)NN=1 HIHOEGPXVVKJPP-JTQLQIEISA-N 0.000 description 2
- SLXKOJJOQWFEFD-UHFFFAOYSA-N 6-aminohexanoic acid Chemical compound NCCCCCC(O)=O SLXKOJJOQWFEFD-UHFFFAOYSA-N 0.000 description 2
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 2
- VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 description 2
- XKRFYHLGVUSROY-UHFFFAOYSA-N Argon Chemical compound [Ar] XKRFYHLGVUSROY-UHFFFAOYSA-N 0.000 description 2
- REDUQXCPUSNJOL-UHFFFAOYSA-N C(C1=CC=CC=C1)NC(CN(C(C1=CC=C(C=C1)C(C)C)=O)CC1=CC=C(C=C1)C(NO)=O)=O Chemical compound C(C1=CC=CC=C1)NC(CN(C(C1=CC=C(C=C1)C(C)C)=O)CC1=CC=C(C=C1)C(NO)=O)=O REDUQXCPUSNJOL-UHFFFAOYSA-N 0.000 description 2
- CYSWUSAYJNCAKA-FYJFLYSWSA-N ClC1=C(C=CC=2N=C(SC=21)OCC)OC1=CC=C(C=N1)/C=C/[C@H](C)NC(C)=O Chemical compound ClC1=C(C=CC=2N=C(SC=21)OCC)OC1=CC=C(C=N1)/C=C/[C@H](C)NC(C)=O CYSWUSAYJNCAKA-FYJFLYSWSA-N 0.000 description 2
- QBXVXKRWOVBUDB-GRKNLSHJSA-N ClC=1C(=CC(=C(CN2[C@H](C[C@H](C2)O)C(=O)O)C1)OCC1=CC(=CC=C1)C#N)OCC1=C(C(=CC=C1)C1=CC2=C(OCCO2)C=C1)C Chemical compound ClC=1C(=CC(=C(CN2[C@H](C[C@H](C2)O)C(=O)O)C1)OCC1=CC(=CC=C1)C#N)OCC1=C(C(=CC=C1)C1=CC2=C(OCCO2)C=C1)C QBXVXKRWOVBUDB-GRKNLSHJSA-N 0.000 description 2
- 229940125761 Compound 6g Drugs 0.000 description 2
- OKKJLVBELUTLKV-MZCSYVLQSA-N Deuterated methanol Chemical compound [2H]OC([2H])([2H])[2H] OKKJLVBELUTLKV-MZCSYVLQSA-N 0.000 description 2
- 238000002965 ELISA Methods 0.000 description 2
- 101000652482 Homo sapiens TBC1 domain family member 8 Proteins 0.000 description 2
- 108010007622 LDL Lipoproteins Proteins 0.000 description 2
- 102000007330 LDL Lipoproteins Human genes 0.000 description 2
- 241000699666 Mus <mouse, genus> Species 0.000 description 2
- 241000700159 Rattus Species 0.000 description 2
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical class [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 2
- 208000006011 Stroke Diseases 0.000 description 2
- 102100030302 TBC1 domain family member 8 Human genes 0.000 description 2
- SRVFFFJZQVENJC-IHRRRGAJSA-N aloxistatin Chemical compound CCOC(=O)[C@H]1O[C@@H]1C(=O)N[C@@H](CC(C)C)C(=O)NCCC(C)C SRVFFFJZQVENJC-IHRRRGAJSA-N 0.000 description 2
- 125000003277 amino group Chemical group 0.000 description 2
- 235000011114 ammonium hydroxide Nutrition 0.000 description 2
- 238000010171 animal model Methods 0.000 description 2
- 239000012300 argon atmosphere Substances 0.000 description 2
- OSVHLUXLWQLPIY-KBAYOESNSA-N butyl 2-[(6aR,9R,10aR)-1-hydroxy-9-(hydroxymethyl)-6,6-dimethyl-6a,7,8,9,10,10a-hexahydrobenzo[c]chromen-3-yl]-2-methylpropanoate Chemical compound C(CCC)OC(C(C)(C)C1=CC(=C2[C@H]3[C@H](C(OC2=C1)(C)C)CC[C@H](C3)CO)O)=O OSVHLUXLWQLPIY-KBAYOESNSA-N 0.000 description 2
- 229910052799 carbon Inorganic materials 0.000 description 2
- 239000012295 chemical reaction liquid Substances 0.000 description 2
- 229940125904 compound 1 Drugs 0.000 description 2
- 208000029078 coronary artery disease Diseases 0.000 description 2
- 238000001212 derivatisation Methods 0.000 description 2
- UREBDLICKHMUKA-CXSFZGCWSA-N dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 description 2
- 229960003957 dexamethasone Drugs 0.000 description 2
- 239000003480 eluent Substances 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 238000001914 filtration Methods 0.000 description 2
- 125000000524 functional group Chemical group 0.000 description 2
- 238000004128 high performance liquid chromatography Methods 0.000 description 2
- 238000005984 hydrogenation reaction Methods 0.000 description 2
- 208000015210 hypertensive heart disease Diseases 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- 239000007791 liquid phase Substances 0.000 description 2
- 230000007774 longterm Effects 0.000 description 2
- QAPTWHXHEYAIKG-RCOXNQKVSA-N n-[(1r,2s,5r)-5-(tert-butylamino)-2-[(3s)-2-oxo-3-[[6-(trifluoromethyl)quinazolin-4-yl]amino]pyrrolidin-1-yl]cyclohexyl]acetamide Chemical compound CC(=O)N[C@@H]1C[C@H](NC(C)(C)C)CC[C@@H]1N1C(=O)[C@@H](NC=2C3=CC(=CC=C3N=CN=2)C(F)(F)F)CC1 QAPTWHXHEYAIKG-RCOXNQKVSA-N 0.000 description 2
- PHVXTQIROLEEDB-UHFFFAOYSA-N n-[2-(2-chlorophenyl)ethyl]-4-[[3-(2-methylphenyl)piperidin-1-yl]methyl]-n-pyrrolidin-3-ylbenzamide Chemical compound CC1=CC=CC=C1C1CN(CC=2C=CC(=CC=2)C(=O)N(CCC=2C(=CC=CC=2)Cl)C2CNCC2)CCC1 PHVXTQIROLEEDB-UHFFFAOYSA-N 0.000 description 2
- 230000021962 pH elevation Effects 0.000 description 2
- 239000002245 particle Substances 0.000 description 2
- 230000002093 peripheral effect Effects 0.000 description 2
- 239000004033 plastic Substances 0.000 description 2
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- DCKVNWZUADLDEH-UHFFFAOYSA-N sec-butyl acetate Chemical compound CCC(C)OC(C)=O DCKVNWZUADLDEH-UHFFFAOYSA-N 0.000 description 2
- 238000000926 separation method Methods 0.000 description 2
- 229910000029 sodium carbonate Inorganic materials 0.000 description 2
- GEHJYWRUCIMESM-UHFFFAOYSA-L sodium sulfite Chemical class [Na+].[Na+].[O-]S([O-])=O GEHJYWRUCIMESM-UHFFFAOYSA-L 0.000 description 2
- VPMIAOSOTOODMY-KJAPKAAFSA-N (4r)-6-[(e)-2-[6-tert-butyl-4-(4-fluorophenyl)-2-propan-2-ylpyridin-3-yl]ethenyl]-4-hydroxyoxan-2-one Chemical compound C([C@H](O)C1)C(=O)OC1/C=C/C=1C(C(C)C)=NC(C(C)(C)C)=CC=1C1=CC=C(F)C=C1 VPMIAOSOTOODMY-KJAPKAAFSA-N 0.000 description 1
- OJOFMLDBXPDXLQ-VIFPVBQESA-N (4s)-4-benzyl-1,3-oxazolidin-2-one Chemical compound C1OC(=O)N[C@H]1CC1=CC=CC=C1 OJOFMLDBXPDXLQ-VIFPVBQESA-N 0.000 description 1
- 125000006582 (C5-C6) heterocycloalkyl group Chemical group 0.000 description 1
- ITJWNXBZSFIJTP-UHFFFAOYSA-N 1-(bromomethyl)-3-phenylmethoxybenzene Chemical compound BrCC1=CC=CC(OCC=2C=CC=CC=2)=C1 ITJWNXBZSFIJTP-UHFFFAOYSA-N 0.000 description 1
- DAUWIPUGOIFZNF-UHFFFAOYSA-N 1-bromo-3-(bromomethyl)-5-fluorobenzene Chemical compound FC1=CC(Br)=CC(CBr)=C1 DAUWIPUGOIFZNF-UHFFFAOYSA-N 0.000 description 1
- ZPCJPJQUVRIILS-UHFFFAOYSA-N 1-bromo-3-(bromomethyl)benzene Chemical compound BrCC1=CC=CC(Br)=C1 ZPCJPJQUVRIILS-UHFFFAOYSA-N 0.000 description 1
- MNZPFYUUDBYKMD-UHFFFAOYSA-N 2,3,4,5,6-pentachlorophenol;hydrochloride Chemical compound Cl.OC1=C(Cl)C(Cl)=C(Cl)C(Cl)=C1Cl MNZPFYUUDBYKMD-UHFFFAOYSA-N 0.000 description 1
- ZXFLMSIMHISJFV-UHFFFAOYSA-N 2-[1-[(2-methylpropan-2-yl)oxycarbonyl]piperidin-4-yl]acetic acid Chemical compound CC(C)(C)OC(=O)N1CCC(CC(O)=O)CC1 ZXFLMSIMHISJFV-UHFFFAOYSA-N 0.000 description 1
- QLVGHFBUSGYCCG-UHFFFAOYSA-N 2-amino-n-(1-cyano-2-phenylethyl)acetamide Chemical compound NCC(=O)NC(C#N)CC1=CC=CC=C1 QLVGHFBUSGYCCG-UHFFFAOYSA-N 0.000 description 1
- UAIUNKRWKOVEES-UHFFFAOYSA-N 3,3',5,5'-tetramethylbenzidine Chemical compound CC1=C(N)C(C)=CC(C=2C=C(C)C(N)=C(C)C=2)=C1 UAIUNKRWKOVEES-UHFFFAOYSA-N 0.000 description 1
- 125000003542 3-methylbutan-2-yl group Chemical group [H]C([H])([H])C([H])(*)C([H])(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 1
- 101100096578 Arabidopsis thaliana SQD2 gene Proteins 0.000 description 1
- 239000012388 BrettPhos 3rd generation precatalyst Substances 0.000 description 1
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- IAZDPXIOMUYVGZ-WFGJKAKNSA-N Dimethyl sulfoxide Chemical group [2H]C([2H])([2H])S(=O)C([2H])([2H])[2H] IAZDPXIOMUYVGZ-WFGJKAKNSA-N 0.000 description 1
- MYMOFIZGZYHOMD-UHFFFAOYSA-N Dioxygen Chemical compound O=O MYMOFIZGZYHOMD-UHFFFAOYSA-N 0.000 description 1
- 206010014486 Elevated triglycerides Diseases 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- PIICEJLVQHRZGT-UHFFFAOYSA-N Ethylenediamine Chemical compound NCCN PIICEJLVQHRZGT-UHFFFAOYSA-N 0.000 description 1
- BDAGIHXWWSANSR-UHFFFAOYSA-M Formate Chemical compound [O-]C=O BDAGIHXWWSANSR-UHFFFAOYSA-M 0.000 description 1
- 230000005526 G1 to G0 transition Effects 0.000 description 1
- 101000801643 Homo sapiens Retinal-specific phospholipid-transporting ATPase ABCA4 Proteins 0.000 description 1
- 108010033266 Lipoprotein(a) Proteins 0.000 description 1
- 102000004895 Lipoproteins Human genes 0.000 description 1
- 108090001030 Lipoproteins Proteins 0.000 description 1
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 1
- 102100033617 Retinal-specific phospholipid-transporting ATPase ABCA4 Human genes 0.000 description 1
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 1
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 1
- HEDRZPFGACZZDS-MICDWDOJSA-N Trichloro(2H)methane Chemical class [2H]C(Cl)(Cl)Cl HEDRZPFGACZZDS-MICDWDOJSA-N 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- YLEIFZAVNWDOBM-ZTNXSLBXSA-N ac1l9hc7 Chemical compound C([C@H]12)C[C@@H](C([C@@H](O)CC3)(C)C)[C@@]43C[C@@]14CC[C@@]1(C)[C@@]2(C)C[C@@H]2O[C@]3(O)[C@H](O)C(C)(C)O[C@@H]3[C@@H](C)[C@H]12 YLEIFZAVNWDOBM-ZTNXSLBXSA-N 0.000 description 1
- 239000012445 acidic reagent Substances 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 125000001931 aliphatic group Chemical group 0.000 description 1
- 150000001412 amines Chemical class 0.000 description 1
- 229960002684 aminocaproic acid Drugs 0.000 description 1
- 229910052786 argon Inorganic materials 0.000 description 1
- 238000011914 asymmetric synthesis Methods 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 239000012752 auxiliary agent Substances 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- QMMFTRJQCCVPCE-UHFFFAOYSA-N benzyl n-(2-aminoethyl)carbamate Chemical compound NCCNC(=O)OCC1=CC=CC=C1 QMMFTRJQCCVPCE-UHFFFAOYSA-N 0.000 description 1
- HREXFDIZSAUXBO-UHFFFAOYSA-N benzyl n-(2-bromoethyl)carbamate Chemical compound BrCCNC(=O)OCC1=CC=CC=C1 HREXFDIZSAUXBO-UHFFFAOYSA-N 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 229960002685 biotin Drugs 0.000 description 1
- 235000020958 biotin Nutrition 0.000 description 1
- 239000011616 biotin Substances 0.000 description 1
- UORVGPXVDQYIDP-BJUDXGSMSA-N borane Chemical class [10BH3] UORVGPXVDQYIDP-BJUDXGSMSA-N 0.000 description 1
- UWTDFICHZKXYAC-UHFFFAOYSA-N boron;oxolane Chemical class [B].C1CCOC1 UWTDFICHZKXYAC-UHFFFAOYSA-N 0.000 description 1
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 1
- 229910052794 bromium Inorganic materials 0.000 description 1
- FJDQFPXHSGXQBY-UHFFFAOYSA-L caesium carbonate Chemical compound [Cs+].[Cs+].[O-]C([O-])=O FJDQFPXHSGXQBY-UHFFFAOYSA-L 0.000 description 1
- 229910000024 caesium carbonate Inorganic materials 0.000 description 1
- 238000004364 calculation method Methods 0.000 description 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
- 230000007211 cardiovascular event Effects 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- PBAYDYUZOSNJGU-UHFFFAOYSA-N chelidonic acid Natural products OC(=O)C1=CC(=O)C=C(C(O)=O)O1 PBAYDYUZOSNJGU-UHFFFAOYSA-N 0.000 description 1
- 238000004296 chiral HPLC Methods 0.000 description 1
- 239000012069 chiral reagent Substances 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 239000003593 chromogenic compound Substances 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 229940125782 compound 2 Drugs 0.000 description 1
- 229940126214 compound 3 Drugs 0.000 description 1
- 229940125796 compound 3d Drugs 0.000 description 1
- 229940125898 compound 5 Drugs 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 238000007405 data analysis Methods 0.000 description 1
- 150000001975 deuterium Chemical group 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 229910001882 dioxygen Inorganic materials 0.000 description 1
- 239000002270 dispersing agent Substances 0.000 description 1
- 239000000975 dye Substances 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 239000003623 enhancer Substances 0.000 description 1
- PQVSTLUFSYVLTO-UHFFFAOYSA-N ethyl n-ethoxycarbonylcarbamate Chemical compound CCOC(=O)NC(=O)OCC PQVSTLUFSYVLTO-UHFFFAOYSA-N 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 239000003205 fragrance Substances 0.000 description 1
- 238000003304 gavage Methods 0.000 description 1
- 239000012362 glacial acetic acid Substances 0.000 description 1
- 125000001072 heteroaryl group Chemical group 0.000 description 1
- 125000000623 heterocyclic group Chemical group 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 239000000543 intermediate Substances 0.000 description 1
- PNDPGZBMCMUPRI-UHFFFAOYSA-N iodine Chemical compound II PNDPGZBMCMUPRI-UHFFFAOYSA-N 0.000 description 1
- 239000011630 iodine Substances 0.000 description 1
- 229910052740 iodine Inorganic materials 0.000 description 1
- HVTICUPFWKNHNG-UHFFFAOYSA-N iodoethane Chemical class CCI HVTICUPFWKNHNG-UHFFFAOYSA-N 0.000 description 1
- INQOMBQAUSQDDS-UHFFFAOYSA-N iodomethane Chemical class IC INQOMBQAUSQDDS-UHFFFAOYSA-N 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 1
- 238000006317 isomerization reaction Methods 0.000 description 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 239000007951 isotonicity adjuster Substances 0.000 description 1
- JFOZKMSJYSPYLN-QHCPKHFHSA-N lifitegrast Chemical compound CS(=O)(=O)C1=CC=CC(C[C@H](NC(=O)C=2C(=C3CCN(CC3=CC=2Cl)C(=O)C=2C=C3OC=CC3=CC=2)Cl)C(O)=O)=C1 JFOZKMSJYSPYLN-QHCPKHFHSA-N 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- GLXDVVHUTZTUQK-UHFFFAOYSA-M lithium hydroxide monohydrate Substances [Li+].O.[OH-] GLXDVVHUTZTUQK-UHFFFAOYSA-M 0.000 description 1
- 229940040692 lithium hydroxide monohydrate Drugs 0.000 description 1
- YTJXGDYAEOTOCG-UHFFFAOYSA-N lithium;di(propan-2-yl)azanide;oxolane Chemical compound [Li+].C1CCOC1.CC(C)[N-]C(C)C YTJXGDYAEOTOCG-UHFFFAOYSA-N 0.000 description 1
- UIUXUFNYAYAMOE-UHFFFAOYSA-N methylsilane Chemical compound [SiH3]C UIUXUFNYAYAMOE-UHFFFAOYSA-N 0.000 description 1
- 238000013508 migration Methods 0.000 description 1
- 230000005012 migration Effects 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 125000002950 monocyclic group Chemical group 0.000 description 1
- GVOISEJVFFIGQE-YCZSINBZSA-N n-[(1r,2s,5r)-5-[methyl(propan-2-yl)amino]-2-[(3s)-2-oxo-3-[[6-(trifluoromethyl)quinazolin-4-yl]amino]pyrrolidin-1-yl]cyclohexyl]acetamide Chemical compound CC(=O)N[C@@H]1C[C@H](N(C)C(C)C)CC[C@@H]1N1C(=O)[C@@H](NC=2C3=CC(=CC=C3N=CN=2)C(F)(F)F)CC1 GVOISEJVFFIGQE-YCZSINBZSA-N 0.000 description 1
- 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000000740 n-pentyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000001971 neopentyl group Chemical group [H]C([*])([H])C(C([H])([H])[H])(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 229910052698 phosphorus Inorganic materials 0.000 description 1
- 239000011574 phosphorus Substances 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 125000004482 piperidin-4-yl group Chemical group N1CCC(CC1)* 0.000 description 1
- DNUTZBZXLPWRJG-UHFFFAOYSA-M piperidine-1-carboxylate Chemical compound [O-]C(=O)N1CCCCC1 DNUTZBZXLPWRJG-UHFFFAOYSA-M 0.000 description 1
- 229910000027 potassium carbonate Inorganic materials 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000002335 preservative effect Effects 0.000 description 1
- 229940002612 prodrug Drugs 0.000 description 1
- 239000000651 prodrug Substances 0.000 description 1
- 238000000159 protein binding assay Methods 0.000 description 1
- 239000012460 protein solution Substances 0.000 description 1
- 150000004040 pyrrolidinones Chemical class 0.000 description 1
- 230000000250 revascularization Effects 0.000 description 1
- 125000006413 ring segment Chemical group 0.000 description 1
- 125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 239000001632 sodium acetate Substances 0.000 description 1
- 235000017281 sodium acetate Nutrition 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000012321 sodium triacetoxyborohydride Substances 0.000 description 1
- 230000009870 specific binding Effects 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 239000012089 stop solution Substances 0.000 description 1
- 229910052717 sulfur Inorganic materials 0.000 description 1
- 239000011593 sulfur Substances 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- VFKKJYLKVBRZBD-SFHVURJKSA-N tert-butyl 4-[2-[(4s)-4-benzyl-2-oxo-1,3-oxazolidin-3-yl]-2-oxoethyl]piperidine-1-carboxylate Chemical compound C1CN(C(=O)OC(C)(C)C)CCC1CC(=O)N1C(=O)OC[C@@H]1CC1=CC=CC=C1 VFKKJYLKVBRZBD-SFHVURJKSA-N 0.000 description 1
- 125000001973 tert-pentyl group Chemical group [H]C([H])([H])C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- RWRDLPDLKQPQOW-UHFFFAOYSA-N tetrahydropyrrole Substances C1CCNC1 RWRDLPDLKQPQOW-UHFFFAOYSA-N 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 230000009261 transgenic effect Effects 0.000 description 1
- 238000004704 ultra performance liquid chromatography Methods 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/4025—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
Definitions
- the disclosure belongs to the field of medicine, and relates to a substituted phenylpropionic acid derivative and its application.
- Lipoprotein(a) is a kind of blood lipid particle similar to low-density lipoprotein, which is mainly composed of inner core rich in cholesteryl ester and unique apolipoprotein(a) [Apo(a)].
- the characteristics of long-term stability and long-term stability show a skewed distribution in the population. Studies have found that elevated Lp(a) is associated with an increased risk of cardiovascular events and associated revascularization.
- WO2020247429 reports a class of pyrrolidone lipoprotein inhibitors that bind to human Apo(a) protein. By binding to Apo(a) protein to inhibit the combination of LDL particles and apo(a), to reduce the level of Lp(a) in plasma,
- the compound disclosed in the present disclosure is not disclosed in any literature, and this type of compound exhibits specific binding to human Apo(a) protein, thereby reducing the level of Lp(a) in plasma.
- the disclosure provides a compound shown in formula I or a pharmaceutically acceptable salt thereof,
- R 1 , R 5 are independently selected from hydrogen or C 1-6 alkyl, said alkyl is optionally substituted by one or more R 1A , each R 1A is independently selected from halogen, hydroxyl, cyano or amino ;
- R 2 and R 6 are independently selected from hydrogen, deuterium, halogen or C 1-6 alkyl, the alkyl is optionally substituted by one or more R 2A , each R 2A is independently selected from halogen, hydroxyl, cyano base or amino;
- R 3 and R 7 are independently selected from hydrogen, deuterium, halogen, cyano, C 1-6 alkyl or C 1-6 alkoxy, and the alkyl or alkoxy is optionally replaced by one or more R 3A Substituted, each R 3A is independently selected from halogen, hydroxyl, cyano or amino;
- R 2 , R 3 , R 6 , and R 7 are not hydrogen or methyl at the same time;
- R 4 and R 8 are independently selected from hydrogen or C 1-6 alkyl
- L 1 is selected from -CH 2 NHCH 2 -, -CH 2 NH-, -NH-, -S-, -S(O)-, -S(O) 2 -, -O-, -OCH 2 -, - OCH 2 CH 2 O-, -NHSO 2 NH-,
- R is selected from hydrogen or C 1-6 alkyl, the alkyl is optionally substituted by one or more R 4A , each R 4A is independently selected from halogen, hydroxyl, cyano or amino;
- R b is selected from hydrogen, deuterium, halogen or C 1-6 alkyl, the alkyl is optionally substituted by one or more R 5A , each R 5A is independently selected from halogen, hydroxyl, cyano or amino;
- R is independently selected from hydrogen, deuterium, halogen, cyano, C 1-6 alkyl or C 1-6 alkoxy, the alkyl or alkoxy is optionally substituted by one or more R 6A ,
- Each R 6A is independently selected from halogen, hydroxy, cyano or amino;
- R d is selected from hydrogen or C 1-6 alkyl
- n, m, and o are each independently selected from integers between 0 and 4.
- R 2 and R 6 are independently selected from deuterium.
- R 2 and R 6 in the compound of formula I or a pharmaceutically acceptable salt thereof are independently selected from halogen, such as fluorine or chlorine.
- R 2 and R 6 are independently selected from C 1-6 alkyl, and the alkyl is optionally substituted by one or more R 2A , R 2A as defined above. In some embodiments, in the compound of formula I or a pharmaceutically acceptable salt thereof, R 2 and R 6 are independently selected from methyl, ethyl or propyl.
- R 1 and R 5 are independently selected from hydrogen.
- R 3 and R 7 are independently selected from deuterium or C 1-6 alkoxy, and the alkoxy is optionally replaced by one or more R 3A Substitution, R 3A is as defined above.
- R 3 and R 7 are independently selected from halogen, such as fluorine or chlorine.
- R 3 and R 7 in the compound of formula I or a pharmaceutically acceptable salt thereof are independently selected from C 1-6 alkyl or C 1-6 alkoxy, and the alkyl or alkoxy is optionally Substituted by one or more R 3A , R 3A is as defined above.
- L 1 is selected from -CH 2 NHCH 2 -, -CH 2 NH-, -NH-, -O-, -OCH 2 -, -OCH 2 CH 2 O-, -NHSO 2 NH-, preferably -CH 2 NHCH 2 -, -CH 2 NH-, -NH-, -OCH 2 CH 2 O-.
- L is selected from
- R a , R b , and R c are as defined above.
- R b is selected from deuterium.
- R b is selected from halogen, such as fluorine or chlorine.
- R b in the compound of formula I or a pharmaceutically acceptable salt thereof, is selected from C 1-6 alkyl, and the alkyl is optionally substituted by one or more R 5A , and R 5A is as defined above .
- R b in the compound of formula I or a pharmaceutically acceptable salt thereof is independently selected from methyl, ethyl or propyl.
- R a is selected from hydrogen
- R in the compound of formula I or a pharmaceutically acceptable salt thereof is independently selected from hydrogen or C 1-6 alkoxy, and the alkoxy is optionally substituted by one or more R 6A , R 6A is as defined above.
- R c is independently selected from halogen, such as fluorine or chlorine.
- R in the compound of formula I or a pharmaceutically acceptable salt thereof is independently selected from C 1-6 alkyl or C 1-6 alkoxy, and the alkyl or alkoxy is optionally replaced by one or Substituted by multiple R 6A , R 6A is as defined above.
- the compound of Formula I or a pharmaceutically acceptable salt thereof is selected from:
- Another aspect of the present disclosure also provides a compound represented by formula II or a pharmaceutically acceptable salt thereof,
- R 11 is independently selected from hydrogen or C 1-6 alkyl, said alkyl is optionally substituted by one or more R 11A , each R 11A is independently selected from halogen, hydroxyl, cyano or amino;
- R 12 is independently selected from hydrogen, deuterium, halogen or C 1-6 alkyl, said alkyl is optionally substituted by one or more R 12A , each R 12A is independently selected from halogen, hydroxyl, cyano or amino ;
- R 13 is independently selected from hydrogen, deuterium, halogen, cyano, C 1-6 alkyl or C 1-6 alkoxy, the alkyl or alkoxy is optionally substituted by one or more R 13A , Each R 13A is independently selected from halogen, hydroxy, cyano or amino;
- R 14 is independently selected from hydrogen or C 1-6 alkyl
- W is selected from 3 or 4;
- n1 is selected from an integer between 0-4.
- R 12 is independently selected from hydrogen or deuterium.
- R 12 in the compound of formula II or a pharmaceutically acceptable salt thereof is independently selected from halogen, such as fluorine or chlorine.
- R 12 is independently selected from C 1-6 alkyl, and the alkyl is optionally substituted by one or more R 12A , R 12A is as defined above .
- R 2 and R 6 are independently selected from methyl, ethyl or propyl.
- R 11 in the compound of formula II or a pharmaceutically acceptable salt thereof is independently selected from hydrogen.
- R 13 is independently selected from deuterium or C 1-6 alkoxy, and the alkoxy is optionally substituted by one or more R 13A , R 13A is as defined above.
- R 13 in the compound of formula II or a pharmaceutically acceptable salt thereof is independently selected from halogen, such as fluorine or chlorine.
- L is selected from In other embodiments, in the compound of formula II or its pharmaceutically acceptable salt, L is selected from
- L is selected from
- L 2 is
- the compound represented by formula II or a pharmaceutically acceptable salt thereof is selected from:
- Another aspect of the present disclosure also provides a compound represented by formula III or a pharmaceutically acceptable salt thereof,
- R 21 and R 22 are independently selected from hydrogen, deuterium, halogen, C 1-6 alkyl, C 1-6 alkoxy, four-membered heterocycloalkyl, six-membered heterocycloalkyl, said alkyl , alkoxy, four-membered heterocycloalkyl or six-membered heterocycloalkyl are optionally substituted by one or more R 21A , each R 21A is independently selected from hydrogen, deuterium, halogen or C 1-6 alkyl,
- R 21 , R 22 and adjacent carbon atoms form a 3-6 membered heterocycloalkyl group, the heterocycloalkyl group is optionally substituted by one or more R 22A , each R 22A is independently selected from deuterium, halogen , C 1-6 alkyl;
- R 23 is independently selected from hydrogen, deuterium, halogen, cyano, C 1-6 alkyl or C 1-6 alkoxy, the alkyl or alkoxy is optionally substituted by one or more R 23A , Each R 23A is independently selected from halogen, hydroxyl, cyano or amino;
- R 24 is independently selected from hydrogen or C 1-6 alkyl
- S is selected from an integer between 2-4;
- L 3 is selected from -CH 2 NHCH 2 -, -CH 2 NH-, -NH-, -S-, -S(O)-, -S(O) 2 -, -O-, -OCH 2 -, - OCH 2 CH 2 O-, -NHSO 2 NH-, nitrogen atom,
- n1 is selected from an integer between 0-4.
- R 21 is independently selected from four-membered heterocycloalkyl or six-membered heterocycloalkyl
- R 22 is independently selected from hydrogen, deuterium, halogen, C 1 -6 alkyl or C 1-6 alkoxy, the alkyl, alkoxy, four-membered heterocycloalkyl or six-membered heterocycloalkyl is optionally substituted by one or more R 21A , each of R 21A independently selected from hydrogen, deuterium, halogen, C 1-6 alkyl.
- R 23 is independently selected from deuterium or C 1-6 alkoxy, and the alkoxy is optionally substituted by one or more R 23A , R 23A is as defined above.
- R 23 in the compound of formula III or a pharmaceutically acceptable salt thereof is independently selected from halogen, such as fluorine or chlorine.
- the compound of formula III or a pharmaceutically acceptable salt thereof is
- L 3 , R 22 , R 23 , R 24 , R 21A , n2, and m2 are as defined above.
- L 3 is selected from -CH 2 NHCH 2 -, -CH 2 NH-, -NH-, -S-, -S(O)-, - S(O) 2 -, -O-, -OCH 2 -, -OCH 2 CH 2 O-, -NHSO 2 NH- and
- the compound of formula III or a pharmaceutically acceptable salt thereof is
- L 3 , R 22 , R 23 , R 24 , R 21A and n2 are as defined above.
- R 21 and R 22 in the compound of formula III or a pharmaceutically acceptable salt thereof form a 5- or 6-membered heterocycloalkyl group with adjacent carbon atoms, and the heterocycloalkyl group is optionally replaced by one or more R 22A , R 22A are each independently selected from deuterium, halogen, C 1-6 alkyl.
- the compound of formula III or a pharmaceutically acceptable salt thereof is
- L 3 , R 22 , R 23 , R 24 , R 22A and n2 are as defined above; p is independently selected from an integer between 0-2.
- L 3 is selected from -CH 2 NHCH 2 -, -CH 2 NH-, -NH-, -S-, -S(O)-, -S (O) 2 -, -O-, -OCH 2 -, -OCH 2 CH 2 O-, -NHSO 2 NH-
- the compound of formula III or a pharmaceutically acceptable salt thereof is
- L 3 , R 22 , R 23 , R 24 , R 21A and n2 are as defined above.
- p is independently selected from 1 or 2 in the compound of formula III-c or formula III-c1 or a pharmaceutically acceptable salt thereof.
- L in the compound of formula III-c or formula III-c1 or a pharmaceutically acceptable salt thereof is selected from nitrogen atom,
- L in the compound of formula III-c or formula III-c1 or a pharmaceutically acceptable salt thereof is selected from nitrogen atom,
- R 24 is selected from hydrogen.
- R 23 is selected from hydrogen or C 1-6 alkoxy, and the alkoxy is optionally substituted by one or more R 23A , R 23A is such as the foregoing definition.
- R 23 is selected from halogen, such as fluorine or chlorine.
- R 23 is selected from C 1-6 alkyl or C 1-6 alkoxy, and the alkyl or alkoxy is optionally replaced by one or more Replaced by R 23A , R 23A is as defined above.
- R 21A is selected from hydrogen.
- the compound of Formula III or a pharmaceutically acceptable salt thereof is selected from:
- the present disclosure also provides isotopic substitutions of the foregoing compounds or pharmaceutically acceptable salts thereof.
- the isotopic substitution is deuterated.
- compounds of the present disclosure In competition binding assays, compounds are tested for their in vitro binding affinity to the intended target human apolipoprotein(a).
- the compound of the present disclosure has a good binding ability in combination with apolipoprotein (a).
- compounds of the present disclosure bind to apolipoprotein (a) with an IC50 value in the range of 0.01 to 500 nM.
- compounds of the present disclosure bind to apolipoprotein (a) with an IC50 value in the range of 0.01 to 100 nM.
- compounds of the present disclosure bind to apolipoprotein (a) with an IC50 value in the range of 0.01 to 20 nM.
- compounds of the present disclosure bind to apolipoprotein (a) with an IC50 value in the range of 0.01 to 20 nM. at 0.1 to 30 nM. In some embodiments, compounds of the disclosure bind to apolipoprotein (a) with an IC50 value of ⁇ 50 nM.
- the present disclosure also provides a pharmaceutical composition, comprising at least one therapeutically effective amount of the compound represented by the aforementioned formula I or II or III or its pharmaceutically acceptable salt, or its isotope substitution and a pharmaceutically acceptable excipient agent.
- the unit dose of the pharmaceutical composition is 0.001 mg-1000 mg.
- the pharmaceutical composition contains 0.01-99.99% of the aforementioned compound or its pharmaceutically acceptable salt or its isotope substitution. In certain embodiments, the pharmaceutical composition contains 0.1-99.9% of the aforementioned compounds or their pharmaceutically acceptable salts or their isotopic substitutions. In some embodiments, the pharmaceutical composition contains 0.5%-99.5% of the aforementioned compounds or their pharmaceutically acceptable salts or their isotope substitutions. In certain embodiments, the pharmaceutical composition contains 1%-99% of the aforementioned compounds or their pharmaceutically acceptable salts or their isotopic substitutions. In some embodiments, the pharmaceutical composition contains 2%-98% of the aforementioned compounds or their pharmaceutically acceptable salts or their isotopic substitutions.
- the pharmaceutical composition contains 0.01%-99.99% of pharmaceutically acceptable excipients based on the total weight of the composition. In certain embodiments, the pharmaceutical composition contains 0.1%-99.9% of pharmaceutically acceptable excipients. In certain embodiments, the pharmaceutical composition contains 0.5%-99.5% of pharmaceutically acceptable excipients. In certain embodiments, the pharmaceutical composition contains 1%-99% of pharmaceutically acceptable excipients. In certain embodiments, the pharmaceutical composition contains 2%-98% of pharmaceutically acceptable excipients.
- the present disclosure also provides a method for preventing and/or treating diseases or conditions associated with elevated plasma levels of LP(a), by administering to the patient a therapeutically effective amount of the compound shown in the aforementioned formula I or II or III Or its pharmaceutically acceptable salt or its isotope substitution, or the aforementioned pharmaceutical composition.
- the disease or condition associated with elevated plasma levels of LP(a) is selected from cardiovascular diseases, including but not limited to stroke, hypertensive heart disease, coronary disease.
- the present disclosure also provides a method for preventing and/or treating patients with cardiovascular disease, which comprises administering to the patient a therapeutically effective amount of a compound represented by the aforementioned formula I or formula II or formula III or a pharmaceutically acceptable salt thereof or Its isotope substitution, or the aforementioned pharmaceutical composition.
- the present disclosure also provides a compound or a pharmaceutically acceptable salt thereof as shown in the aforementioned formula I or formula II or formula III or the aforementioned pharmaceutical composition used for the prevention and/or treatment of diseases associated with elevated plasma levels of LP(a) or use in medicine for a disease.
- the disease or condition associated with elevated plasma levels of LP(a) is selected from cardiovascular diseases, including but not limited to stroke, hypertensive heart disease, coronary disease.
- the present disclosure also provides the use of the compound represented by the aforementioned formula I or formula II or formula III, or a pharmaceutically acceptable salt thereof, or the aforementioned pharmaceutical composition in the preparation of a medicament for preventing and/or treating cardiovascular diseases.
- compositions described in the present disclosure may be selected from inorganic or organic salts.
- Compounds of the present disclosure may exist in particular geometric or stereoisomeric forms. This disclosure contemplates all such compounds, including cis and trans isomers, (-)- and (+)-enantiomers, (R)- and (S)-enantiomers, diastereomers isomers, (D)-isomers, (L)-isomers, and their racemic and other mixtures, such as enantiomerically or diastereomerically enriched mixtures, all of which are within the scope of this disclosure. Additional asymmetric carbon atoms may be present in substituents such as alkyl groups. All such isomers, as well as mixtures thereof, are included within the scope of this disclosure. Compounds of the present disclosure containing asymmetric carbon atoms can be isolated in optically pure or racemic forms. Optically pure forms can be resolved from racemic mixtures or synthesized by using chiral starting materials or reagents.
- Optically active (R)- and (S)-isomers as well as D and L-isomers can be prepared by chiral synthesis or chiral reagents or other conventional techniques. If one enantiomer of a compound of the present disclosure is desired, it can be prepared by asymmetric synthesis or derivatization with chiral auxiliary agents, wherein the resulting diastereomeric mixture is separated and the auxiliary group is cleaved to provide pure desired enantiomer.
- a diastereoisomeric salt is formed with an appropriate optically active acid or base, and then a diastereomeric salt is formed by a conventional method known in the art. Diastereomeric resolution is performed and the pure enantiomers are recovered. Furthermore, the separation of enantiomers and diastereomers is usually accomplished by the use of chromatography using chiral stationary phases, optionally in combination with chemical derivatization methods (e.g. amines to amino groups formate).
- the bond Indicates unassigned configuration, i.e. if chiral isomers exist in the chemical structure, the bond can be or or both and Two configurations.
- the bond If the configuration is not specified, it can be the Z configuration or the E configuration, or both configurations.
- tautomer or "tautomeric form” refers to structural isomers of different energies that can interconvert via a low energy barrier.
- proton tautomers also known as prototropic tautomers
- lactam-lactim isomerization
- An example of a lactam-lactim equilibrium is between A and B as shown below.
- the present disclosure also includes certain isotopically labeled compounds of the disclosure that are identical to those described herein, but wherein one or more atoms are replaced by an atom of an atomic mass or mass number different from that normally found in nature.
- isotopes that can be incorporated into compounds of the present disclosure include isotopes of hydrogen, carbon, nitrogen, oxygen, phosphorus, sulfur, fluorine, iodine, and chlorine, such as 2 H, 3 H, 11 C, 13 C, 14 C, 13 N, 15 N, 15 O, 17 O, 18 O, 31 P, 32 P, 35 S, 18 F, 123 I, 125 I and 36 Cl, etc.
- deuterium when a position is specifically designated as deuterium (D), the position is understood to have an abundance of deuterium (i.e., at least 10 % deuterium incorporation).
- exemplary compounds having a natural abundance greater than deuterium can be at least 1000 times more abundant deuterium, at least 2000 times more abundant deuterium, at least 3000 times more abundant deuterium, at least 4000 times more abundant deuterium, at least 5000 times more abundant deuterium, at least 6000 times more abundant deuterium, or more abundant deuterium.
- the present disclosure also includes various deuterated forms of compounds of formula (I). Each available hydrogen atom attached to a carbon atom can be independently replaced by a deuterium atom.
- deuterated starting materials can be used in the preparation of deuterated forms of compounds of formula (I), or they can be synthesized using conventional techniques using deuterated reagents, including but not limited to deuterated borane, trideuterated Borane tetrahydrofuran solution, deuterated lithium aluminum hydride, deuterated ethyl iodide and deuterated methyl iodide, etc.
- C 1-6 alkyl optionally substituted by halogen or cyano means that halogen or cyano may but not necessarily exist, and this description includes the case where the alkyl is substituted by halogen or cyano and the alkyl is not substituted by halogen And the case of cyano substitution.
- “Pharmaceutical composition” means a mixture containing one or more compounds described herein, or a physiologically acceptable salt or prodrug thereof, and other chemical components, as well as other components such as physiologically acceptable carriers and excipients. agent.
- the purpose of the pharmaceutical composition is to promote the administration to the organism, facilitate the absorption of the active ingredient and thus exert biological activity.
- “Pharmaceutically acceptable excipient” includes, but is not limited to, any adjuvant, carrier, excipient, glidant, sweetener, diluent, preservative, agent, dye/colorant, fragrance enhancer, surfactant, wetting agent, dispersant, suspending agent, stabilizer, isotonic agent, solvent or emulsifier.
- an “effective amount” or “therapeutically effective amount” as used in this disclosure includes an amount sufficient to ameliorate or prevent a symptom or condition of a medical condition.
- An effective amount also means an amount sufficient to permit or facilitate diagnosis.
- Effective amounts for a particular patient or veterinary subject may vary depending on factors such as the condition being treated, the general health of the patient, the method, route and dosage of administration, and the severity of side effects.
- An effective amount may be the maximum dose or dosing regimen that avoids significant side effects or toxic effects.
- Alkyl means a saturated aliphatic hydrocarbon group, including straight and branched chain groups of 1 to 6 carbon atoms. Non-limiting examples include methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, tert-butyl, sec-butyl, n-pentyl, 1,1-dimethylpropyl, 1,2-dimethylpropyl, 2,2-dimethylpropyl and various branched isomers, etc.
- Alkyl groups may be substituted or unsubstituted, and when substituted, the substituents may be substituted at any available point of attachment, preferably one or more of the following groups, independently selected from halogen, hydroxy, cyano, or Amino.
- heterocycloalkyl refers to a saturated or partially unsaturated monocyclic or polycyclic cyclic hydrocarbon substituent containing 3 to 6 ring atoms
- heterocycloalkyl include: etc.
- Heterocycloalkyl groups may be optionally substituted or unsubstituted, and when substituted, the substituents are preferably one or more of the following groups independently selected from hydrogen, deuterium, halogen or C 1-6 alkyl.
- alkoxy refers to -O-(alkyl), wherein alkyl is as defined above.
- alkoxy include: methoxy, ethoxy, propoxy, butoxy, cyclopropoxy, cyclobutoxy, cyclopentyloxy, cyclohexyloxy.
- Alkoxy groups may be optionally substituted or unsubstituted, and when substituted, the substituents are preferably one or more of the following groups independently selected from halogen, hydroxy, cyano or amino.
- heterocyclic ring refers to atoms other than carbon atoms that make up the ring, and includes heterocycloalkyl and heteroaryl rings.
- hydroxyl refers to a -OH group.
- halogen refers to fluorine, chlorine, bromine or iodine.
- cyano refers to -CN.
- amino refers to -NH2 .
- Substituted means that one or more hydrogen atoms in a group, preferably up to 5, more preferably 1 to 3 hydrogen atoms are independently substituted by the corresponding number of substituents. It goes without saying that substituents are only in their possible chemical positions and that a person skilled in the art can determine (by experiment or theory) possible or impossible substitutions without undue effort.
- NMR nuclear magnetic resonance
- MS mass spectroscopy
- HPLC HP pressure liquid chromatography
- ACQUITY UPLC BEH C18 1.7UM 2.1X50MM chromatographic column, Ultimate XB-C18 3. 0*150mm Column or Xtimate C18 2.1*30mm column.
- MS uses a Waters SQD2 mass spectrometer to scan in positive/negative ion mode, and the mass scanning range is 100-1200.
- Chiralpak IC-3 100 ⁇ 4.6mm I.D., 3um, Chiralpak AD-3 150 ⁇ 4.6mm I.D., 3um, Chiralpak AD-3 50 ⁇ 4.6mm I.D., 3um, Chiralpak AS-3 150 ⁇ 4.6mm for chiral HPLC analysis and determination I.D., 3um, Chiralpak AS-3 100 ⁇ 4.6mm I.D., 3 ⁇ m, ChiralCel OD-3 150 ⁇ 4.6mm I.D., 3um, Chiralcel OD-3 100 ⁇ 4.6mm I.D., 3 ⁇ m, ChiralCel OJ-H 150 ⁇ 4.6mm I.D., 5um, Chiralcel OJ-3 150 ⁇ 4.6mm I.D., 3um column;
- the thin-layer chromatography silica gel plate uses Yantai Huanghai HSGF254 or Qingdao GF254 silica gel plate.
- the specification of the silica gel plate used in thin-layer chromatography (TLC) is 0.15mm-0.2mm, and the specification of thin-layer chromatography separation and purification products is 0.4mm. ⁇ 0.5mm.
- the flash column purification system uses Combiflash Rf150 (TELEDYNE ISCO) or Isolara one (Biotage).
- Forward column chromatography generally uses Yantai Huanghai silica gel 100-200 mesh, 200-300 mesh or 300-400 mesh silica gel as the carrier, or Changzhou Santai pre-packed pre-packed ultra-pure normal-phase silica gel column (40-63 ⁇ m, 60, 12g ,, 25g, 40g, 80g or other specifications).
- Reversed-phase column chromatography generally uses Changzhou Santai pre-packed ultra-pure C18 silica gel column (20-45 ⁇ m, 40g, 80g, 120g, 220g or other specifications).
- the high-pressure column purification system uses Waters AutoP, together with Waters XBridge BEH C18 OBD Prep Column, 5 ⁇ m, 19mm X 150mm or Atlantis T3 OBD Prep Column, 5 ⁇ m, 19mm X 150mm.
- the chiral preparative column uses DAICEL CHIRALPAK IC (250mm*30mm, 10um) or Phenomenex-Amylose-1 (250mm*30mm, 5um).
- the known starting materials in this disclosure can be adopted or synthesized according to methods known in the art, or can be purchased from Shanghai Titan Technology, ABCR GmbH&Co.KG, Acros Organics, Aldrich Chemical Company, Shaoyuan Chemical Technology (Accela ChemBio Inc), Darui Chemicals and other companies.
- the reactions can all be carried out under an argon atmosphere or a nitrogen atmosphere.
- the argon atmosphere or nitrogen atmosphere means that the reaction bottle is connected to an argon or nitrogen balloon with a volume of about 1 L.
- the hydrogen atmosphere means that the reaction bottle is connected to a hydrogen balloon with a capacity of about 1L.
- the pressurized hydrogenation reaction uses a Parr 3916EKX hydrogenator and Qinglan QL-500 hydrogen generator or HC2-SS hydrogenator.
- the hydrogenation reaction is usually vacuumized and filled with hydrogen, and the operation is repeated 3 times.
- the solution refers to an aqueous solution.
- reaction temperature is room temperature, which is 20°C to 30°C.
- the monitoring of the reaction progress in the embodiment adopts thin-layer chromatography (TLC), the developing agent used in reaction, the eluent system of the eluent system of the column chromatography that purification compound adopts and the developing agent system of thin-layer chromatography, the volume of solvent
- TLC thin-layer chromatography
- the ratio is adjusted according to the polarity of the compound, and it can also be adjusted by adding a small amount of basic or acidic reagents such as triethylamine and acetic acid.
- Step 3 Preparation of (S)-3-(3-bromo-5-fluorophenyl)-2-((R)-1-(tert-butoxycarbonyl)pyrrolidin-3-yl)propanoic acid (1d)
- compound 1c (2 g, 3.5 mol) was dissolved in tetrahydrofuran (20 mL), and after adding 1M hydrogen peroxide (5 mL), 0.5 M lithium hydroxide aqueous solution (10 mL) was slowly added dropwise, and the reaction was monitored by LCMS. After the reaction was completed, saturated sodium sulfite (10 mL) was added dropwise to quench the reaction, and stirred for 5-10 minutes.
- reaction solution was cooled to room temperature, centrifuged and filtered, and the filtrate was purified by reverse-phase flash column chromatography (acetonitrile/water) to obtain compound 1f (173 mg, yield 50%) as a yellow oil.
- Step 6 (R)-3-((S)-3-(3-(aminomethyl)-5-fluorophenyl)-1-(tert-butoxy)-1-oxopropan-2-yl ) Preparation of pyrrolidine-1-carboxylic acid tert-butyl ester (1g)
- Step 7 (3R)-3-[(2S)-3-(3- ⁇ [bis( ⁇ 3-[(2S)-3-(tert-butoxy)-2-[(3R)-1-[ (tert-butoxy)carbonyl]pyrrolidin-3-yl]-3-propionyl]-5-fluorophenyl ⁇ methyl)amino]methyl ⁇ -5-fluorophenyl)-1-(tert-butoxy
- Step 8 (2S)-3-(3- ⁇ [bis( ⁇ 3-[(2S)-2-carboxy-2-[(3R)-pyrrolidin-3-yl]ethyl]-5-fluorobenzene Preparation of base ⁇ methyl)amino]methyl ⁇ -5-fluorophenyl)-2-[(3R)-pyrrolidin-3-yl]propionic acid (1)
- Step 1 (S)-tert-butyl 4-(2-(4-benzyl-2-oxooxazolidin-3-yl)-2-oxoethyl)piperidine-1-carboxylate (2b ) preparation
- reaction solution was warmed to room temperature and stirred for 24 hours.
- 2M aqueous hydrochloric acid 250 mL was added, the organic phase was separated and concentrated, and the residue was purified by silica gel flash column chromatography (petroleum ether/ethyl acetate) to obtain oily liquid compound 2b (8 g, yield 96.7%).
- Step 2 4-((S)-1-((S)-4-Benzyl-2-oxooxazolidin-3-yl)-3-(3-bromophenyl)-1-oxopropane Preparation of -2-yl)piperidine-1-carboxylate tert-butyl ester (2c)
- Step 3 Preparation of (S)-3-(3-bromophenyl)-2-(1-(tert-butoxycarbonyl)piperidin-4-yl)propanoic acid (2d)
- compound 2c (1.5 g, 2.6 mol) was dissolved in tetrahydrofuran (15 mL), and after adding 1M hydrogen peroxide (3.5 mL), 0.5 M lithium hydroxide aqueous solution (7 mL) was slowly added dropwise, and the reaction was monitored by LCMS. After the reaction was completed, saturated sodium sulfite (8 mL) was added dropwise to quench the reaction, and stirred for 5-10 minutes.
- Step 4 (S)-tert-butyl 4-(3-(3-bromobenzene)-1-(tert-butoxy)-1-oxopropan-2-yl)piperidine-1-carboxylate (2e ) preparation
- reaction solution was cooled to room temperature, centrifuged and filtered, and the filtrate was purified by reverse-phase flash column chromatography (acetonitrile/water) to obtain yellow oily compound 2f (180 mg, yield 33.7%).
- Step 7 4-[(2S)-3-(3- ⁇ [Bis( ⁇ 3-[(2S)-3-(tert-butoxy)-2- ⁇ 1-[(tert-butoxy)carbonyl] Piperidin-4-yl ⁇ -3-propionyl]phenyl ⁇ methyl)amino]methyl ⁇ phenyl)-1-(tert-butoxy)-1-oxopropan-2-yl]piperidine- Preparation of tert-butyl 1-carboxylate (2h)
- Step 8 (2S)-3-(3- ⁇ [Bis( ⁇ 3-[(2S)-2-carboxylic acid-2-(piperidin-4-yl)ethyl]phenyl ⁇ methyl)amino] Preparation of methyl ⁇ phenyl)-2-(piperidin-4-yl)propionic acid (2)
- Dissolve compound 3a (2.4g, 5.28mmol) prepared according to the method in patent WO2020247429 in anhydrous tetrahydrofuran (50mL), cool to -78°C, add 2M lithium diisopropylamide tetrahydrofuran solution (5.28mL), and react at low temperature After 30 minutes, N-fluorobisbenzenesulfonamide (5.0 g, 15.85 mmol) was added. The reaction was gradually warmed to room temperature and reacted for 16 hours. After the completion of the reaction was detected by LCMS, saturated ammonium chloride solution was added to the reaction solution, and extracted with ethyl acetate (20 mL ⁇ 2).
- Step 5 3-[3-( ⁇ bis[(3- ⁇ 2-carboxy-2-fluoro-2-[(3S)-pyrrolidin-3-yl]ethyl ⁇ phenyl)methyl]amino ⁇ methanol yl)phenyl]-2-fluoro-2-[(3S)-pyrrolidin-3-yl]propionic acid (3)
- reaction liquid was cooled to room temperature and centrifuged, and the filtrate was purified by reverse-phase flash column chromatography (acetonitrile/water) to obtain compound 4a (270 mg, yield 76%) as a yellow oil.
- Step 2 (3R)-3-[(2S)-3- ⁇ 3-[( ⁇ 2-[bis( ⁇ 3-[(2S)-3-(tert-butoxy)-2-[(3R) -1-[(tert-butoxy)carbonyl]pyrrolidin-3-yl]-3-propionyl]phenyl ⁇ methyl)amino]ethyl ⁇ ( ⁇ 3-[(2S)-3-(tert-butyl Oxygen)-2-[(3R)-1-[(tert-butoxy)carbonyl]pyrrolidin-3-yl]-3-propionyl]phenyl ⁇ methyl)amino)methyl]phenyl ⁇ - 1-(tert-butoxy)-1-oxopropan-2-yl]pyrrolidine-1-carboxylic acid tert-butyl ester (4b) and (3R)-3-[(2S)-1-(tert-butoxy Base)-3-(3- ⁇ [( ⁇ 3-[(2S)-3-(tert
- compound 1b (10.0g, 25.74mmol) was dissolved in tetrahydrofuran (10mL), cooled to -30°C, 1M bis(trimethylsilyl)amide lithium tetrahydrofuran solution (31mL, 31mmol) was added dropwise, and the addition was completed Reaction lasted for 30 minutes; a solution of 3-benzyloxybenzyl bromide (8.56g, 30.89mmol) in tetrahydrofuran (15mL) was added dropwise, reacted for 1 hour, and heated to 0°C-5°C overnight.
- Step 2 Preparation of (S)-3-(3-(benzyloxy)phenyl)-2-((R)-1-(tert-butoxycarbonyl)pyrrolidin-3-yl)propanoic acid (6b)
- Step 7 (3R)-3-[(2S)-1-(tert-butoxy)-3-(3- ⁇ [(2- ⁇ 3-[(2S)-3-(tert-butoxy)- 2-[(3R)-1-[(tert-butoxy)carbonyl]pyrrolidin-3-yl]-3-oxopropyl]phenoxy ⁇ ethyl)( ⁇ 3-[(2S)-3 -(tert-butoxy)-2-[(3R)-1-[(tert-butoxy)carbonyl]pyrrolidin-3-yl]-3-oxopropyl]phenyl ⁇ methyl)amino]methyl
- phenyl)-1-oxopropan-2-yl]pyrrolidine-1-carboxylic acid tert-butyl ester (6g)
- Step 8 (2S)-3-(3- ⁇ [(2- ⁇ 3-[(2S)-2-Carboxy-2-[(3R)-pyrrolidin-3-yl]ethyl]phenoxy ⁇ Ethyl)( ⁇ 3-[(2S)-2-carboxy-2-[(3R)-pyrrolidin-3-yl]ethyl]phenyl ⁇ methyl)amino]methyl ⁇ phenyl)-2- Preparation of [(3R)-pyrrolidin-3-yl]propionic acid tetrahydrochloride (6)
- Step 1 (R)-3-((S)-3-(3-((2-(((Benzyloxy)carbonyl)amino)ethyl)amino)phenyl)-1-(tert-butoxy
- Step 2 (R)-3-((S)-3-(3-((2-aminoethyl)amino)phenyl)-1-(tert-butoxy)-1-oxopropane-2- Base) the preparation of pyrrolidine-1-carboxylate tert-butyl ester (7b)
- Step 4 (2S)-3-[3-( ⁇ [2-( ⁇ 3-[(2S)-2-Carboxy-2-[(3R)-pyrrolidin-3-yl]ethyl]phenyl ⁇ Amino)ethyl]( ⁇ 3-[(2S)-2-carboxy-2-[(3R)-pyrrolidin-3-yl]ethyl]phenyl ⁇ methyl)amino ⁇ methyl)phenyl]- Preparation of 2-[(3R)-pyrrolidin-3-yl]propionic acid pentahydrochloride (7)
- Test Example 1 Compound inhibits Lp(a) assembly activity test
- This disclosure uses double antibody ELISA method to detect the assembly efficiency of Apo(a) and ApoB protein, the antibodies are ApoB-Capture antibody (Mabtech) and Apo(a)-Detector antibody (Abcam); the detection samples are human transgenic hApo(a ) and hApoB mouse plasma were diluted 500 times for use.
- reaction solution to the ELISA detection plate pre-coated with ApoB-Capture antibody, incubate at room temperature for 2 hours, and then wash the plate 4 times with washing solution; add biotin-labeled Apo(a)-Detector antibody, and incubate at room temperature for 1 hour , wash the plate and add the chromogenic substrate 3,3',5,5'-tetramethylbenzidine (TMB, purchased from Abcam) solution; after incubating at room temperature for 15 minutes, add the reaction stop solution, mix well and immediately use the enzyme The standard instrument detects the absorbance at 450nm. Finally, GraphPad Prism 9 software was used for data analysis and IC50 calculation.
- TMB 3,3',5,5'-tetramethylbenzidine
- the 0% inhibition rate of Apo (a) and ApoB protein assembly corresponds to the OD value when the compound concentration is 0 (1%DMSO); the 100% inhibition rate of Apo (a) and ApoB protein assembly corresponds to adding only ApoB protein solution ( hApoB mouse plasma dilutions) when the OD value.
- the LC/MS/MS method was used to determine the drug concentration in blood plasma of Beagle dogs at different times after intragastric administration of the compound of the present disclosure. To study the pharmacokinetic behavior of the disclosed compound in Beagle dogs, and evaluate its pharmacokinetic characteristics.
- Drug preparation Weigh a certain amount of drug, add normal saline to make a 2 mg/mL colorless and clear solution.
- Beagle dogs are given the compound of the disclosure by intragastric administration, and about 0.6 mL of blood is collected by peripheral venipuncture at 0.25, 0.5, 1, 2, 4, 6, 8, and 24 hours after administration, and placed in a test tube containing EDTA-K2 , 4°C, centrifuge at 2000 rpm for 10 minutes to separate the plasma, and store it at -75°C.
- Determination of the content of the compound to be tested in Beagle dog plasma at different blood collection time points Take 33 ⁇ L of Beagle dog plasma (30 ⁇ L plasma and 3 ⁇ L blank) taken at various times after administration and add it to 18 ⁇ L of 6% perchloric acid solution, vortex Mix for 30 seconds, centrifuge at 3900 rpm for 15 minutes at 4°C, then add 200 ⁇ L of acetonitrile solution containing internal standard dexamethasone after alkalinization (adjust the pH to 10-11 with ammonia water) to precipitate protein, and vortex for 30 seconds. Centrifuge at 3900 rpm for 15 minutes at 4°C, take the supernatant from the plasma sample, dilute it 3 times with water, and take 8 ⁇ L for LC/MS/MS analysis.
- WinNonlin 6.1 software was used to calculate pharmacokinetic parameters by non-compartmental model method.
- the beagle pharmacokinetic parameters of the disclosed compounds are shown in Table 2 below.
- Compound 6 has better oral absorption in Beagle dogs, better blood exposure, long half-life, excellent pharmacokinetic characteristics, and oral administration has obvious advantages.
- Test Example 3 In vivo pharmacokinetic experiment in cynomolgus monkeys
- the LC/MS/MS method was used to determine the drug concentration in plasma at different times after intragastric administration of the compound of the present disclosure to cynomolgus monkeys.
- the pharmacokinetic behavior of the disclosed compound in cynomolgus monkeys was studied, and its pharmacokinetic characteristics were evaluated.
- mice 2 cynomolgus monkeys (one male and one female) healthy for 24-36 months in each group
- Drug preparation Weigh a certain amount of drug and add physiological saline to make 10 mg/mL (reference substance 1) and 3 mg/mL (compound 6) colorless and clear solutions.
- cynomolgus monkeys administered the compound of the present disclosure by intragastric administration 0.25, 0.5, 1, 2, 4, 6, 8, 24 hours after administration, about 0.5 mL of blood was collected by peripheral venipuncture, and placed in a test tube containing EDTA-K2 , 4°C, centrifuge at 2000 rpm for 10 minutes to separate the plasma, and store it at -75°C.
- Determination of the content of the compound to be tested in cynomolgus monkey plasma at different blood collection time points Take 33 ⁇ L of cynomolgus monkey plasma (30 ⁇ L plasma and 3 ⁇ L blank) taken at various times after administration and add it to 18 ⁇ L of 6% perchloric acid solution, vortex Mix for 30 seconds, centrifuge at 3900 rpm for 15 minutes at 4°C, then add 200 ⁇ L of acetonitrile solution containing internal standard dexamethasone after alkalinization (adjust the pH to 10-11 with ammonia water) to precipitate protein, and vortex for 30 seconds. Centrifuge at 3900 rpm for 15 minutes at 4°C, take the supernatant from the plasma sample, dilute it 3 times with water, and take 8 ⁇ L for LC/MS/MS analysis.
- WinNonlin 6.1 software was used to calculate pharmacokinetic parameters by non-compartmental model method.
- the pharmacokinetic parameters of the compounds of the present disclosure in cynomolgus monkeys are shown in Table 3 below.
- mice were used as test animals, and a high dose of the disclosed compound was orally gavaged, and the mice were clinically observed to evaluate the safety of the disclosed compound.
- mice Take 8 male C57/6J mice, numbered 1-8 respectively, and weigh them. Fasted for 4 hours before the start of the experiment, and weighed after the fast (0h). 6 rats with average body weight were selected into the group, 3 rats in each group, divided into 2 groups.
- the first group (G1) was given the reference substance 1, and the second group (G2) was given the compound Example 6 of the present disclosure.
- the compounds in the G1 and G2 groups were all administered orally by gavage, the dose was 1000mg/kg, and the solvents were all normal saline.
- the mice in the experimental group were clinically observed at 15min, 30min, 1h, 2h, 4h, 6h, and 24h after administration. Both groups were given food 2 hours after the medicine. The body weight of the mice was monitored for 7 consecutive days, and the results are shown in Table 4 below.
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Abstract
Description
化合物 | Lp(a)组装,IC 50(nM) |
1 | 0.75 |
2 | 1.7 |
3 | 1.4 |
4 | 0.85 |
5 | 0.78 |
6 | 0.41 |
7 | 0.76 |
Claims (15)
- 根据权利要求1所述的化合物或其可药用盐,其中R 12独立地选自氢或氘。
- 根据权利要求1或2所述的化合物或其可药用盐,其中R 12独立地选自卤素,例如氟或氯;或者R 12独立地选自C 1-6烷基,所述烷基任选被一个或多个R 12A所取代,R 12A如权利要求1中所定义。
- 根据权利要求1-3任一项所述的化合物或其可药用盐,其中R 11独立地选自氢。
- 根据权利要求1-4任一项所述的化合物或其可药用盐,其中R 13独立地选自氢或氘。
- 根据权利要求1-4任一项所述的化合物或其可药用盐,其中R 13独立地选自氘或C 1-6烷氧基,所述烷氧基任选被一个或多个R 13A所取代,R 13A如权利要求1中定义;或R 13独立地选自卤素,例如氟或氯。
- 根据权利要求1-9任一项所述的化合物或其可药用盐的同位素取代物,优选的,所述同位素取代物为氘代物。
- 一种药物组合物,包括至少一种治疗有效量的如权利要求1-9任一项所述的化合物或其可药用盐、或权利要求10所述的同位素取代物,以及药学上可接受的赋形剂。
- 一种预防和/或治疗与LP(a)血浆水平升高相关的疾病或病症的方法,其通 过向所述患者施用有效量治疗的如权利要求1-9任一项所述的化合物或其可药用盐、或权利要求10所述的同位素取代物、或权利要求11所述的药物组合物。
- 一种预防和/或治疗心血管疾病患者的方法,其通过向所述患者施用治疗有效量的如权利要求1-9任一项所述的化合物或其可药用盐、或权利要求10所述的同位素取代物、或权利要求11所述的药物组合物。
- 根据权利要求1-9任一项所述的化合物或其可药用盐、或权利要求10所述的同位素取代物、或权利要求11所述的药物组合物在制备用于预防和/或治疗与LP(a)血浆水平升高相关的疾病或病症的药物中的用途。
- 根据权利要求1-9任一项所述的化合物或其可药用盐、或权利要求10所述的同位素取代物、或权利要求11所述的药物组合物在制备用于预防和/或治疗心血管疾病的药物中的用途。
Priority Applications (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CA3235992A CA3235992A1 (en) | 2021-11-03 | 2022-11-03 | Substituted phenylpropionic acid derivative and use thereof |
KR1020247017510A KR20240091010A (ko) | 2021-11-03 | 2022-11-03 | 치환된 페닐프로피온산 유도체 및 이의 용도 |
AU2022381258A AU2022381258A1 (en) | 2021-11-03 | 2022-11-03 | Substituted phenylpropionic acid derivative and use thereof |
CN202280066584.5A CN118055927A (zh) | 2021-11-03 | 2022-11-03 | 一种取代的苯丙酸衍生物及其用途 |
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202111293711 | 2021-11-03 | ||
CN202111293711.9 | 2021-11-03 | ||
CN202211033065 | 2022-08-26 | ||
CN202211033065.7 | 2022-08-26 |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2023078333A1 true WO2023078333A1 (zh) | 2023-05-11 |
WO2023078333A8 WO2023078333A8 (zh) | 2023-08-10 |
Family
ID=86240694
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/CN2022/129479 WO2023078333A1 (zh) | 2021-11-03 | 2022-11-03 | 一种取代的苯丙酸衍生物及其用途一种取代的苯丙酸衍生物及其用途 |
Country Status (6)
Country | Link |
---|---|
KR (1) | KR20240091010A (zh) |
CN (1) | CN118055927A (zh) |
AU (1) | AU2022381258A1 (zh) |
CA (1) | CA3235992A1 (zh) |
TW (1) | TW202334116A (zh) |
WO (1) | WO2023078333A1 (zh) |
Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2003016265A1 (fr) * | 2001-08-17 | 2003-02-27 | Eisai Co., Ltd. | Compose cyclique et agoniste du recepteur ppar |
WO2005068410A1 (en) * | 2003-12-24 | 2005-07-28 | Esperion Therapeutics, Inc. | Ether compounds and compositions for cholesterol management and related uses |
WO2005068412A1 (en) * | 2003-12-24 | 2005-07-28 | Esperion Therapeutics, Inc. | Ketone compounds and compositions for cholesterol management and related uses |
CN1894195A (zh) * | 2000-10-11 | 2007-01-10 | 埃斯佩里安医疗公司 | 用于控制胆固醇以及相关用途的醚化合物以及组合物 |
CN1962596A (zh) * | 2000-10-11 | 2007-05-16 | 埃斯佩里安医疗公司 | 用于控制胆固醇以及相关用途的酮化合物以及组合物 |
WO2020247429A1 (en) | 2019-06-07 | 2020-12-10 | Eli Lilly And Company | Pyrrolidine compounds |
-
2022
- 2022-11-03 CA CA3235992A patent/CA3235992A1/en active Pending
- 2022-11-03 TW TW111142050A patent/TW202334116A/zh unknown
- 2022-11-03 KR KR1020247017510A patent/KR20240091010A/ko unknown
- 2022-11-03 CN CN202280066584.5A patent/CN118055927A/zh active Pending
- 2022-11-03 WO PCT/CN2022/129479 patent/WO2023078333A1/zh active Application Filing
- 2022-11-03 AU AU2022381258A patent/AU2022381258A1/en active Pending
Patent Citations (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1894195A (zh) * | 2000-10-11 | 2007-01-10 | 埃斯佩里安医疗公司 | 用于控制胆固醇以及相关用途的醚化合物以及组合物 |
CN1962596A (zh) * | 2000-10-11 | 2007-05-16 | 埃斯佩里安医疗公司 | 用于控制胆固醇以及相关用途的酮化合物以及组合物 |
WO2003016265A1 (fr) * | 2001-08-17 | 2003-02-27 | Eisai Co., Ltd. | Compose cyclique et agoniste du recepteur ppar |
WO2005068410A1 (en) * | 2003-12-24 | 2005-07-28 | Esperion Therapeutics, Inc. | Ether compounds and compositions for cholesterol management and related uses |
WO2005068412A1 (en) * | 2003-12-24 | 2005-07-28 | Esperion Therapeutics, Inc. | Ketone compounds and compositions for cholesterol management and related uses |
WO2020247429A1 (en) | 2019-06-07 | 2020-12-10 | Eli Lilly And Company | Pyrrolidine compounds |
CN114008021A (zh) | 2019-06-07 | 2022-02-01 | 伊莱利利公司 | 吡咯烷化合物 |
Also Published As
Publication number | Publication date |
---|---|
CA3235992A1 (en) | 2023-05-11 |
AU2022381258A1 (en) | 2024-05-02 |
KR20240091010A (ko) | 2024-06-21 |
CN118055927A (zh) | 2024-05-17 |
WO2023078333A8 (zh) | 2023-08-10 |
TW202334116A (zh) | 2023-09-01 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP7124006B2 (ja) | アミロイド標的剤及びその使用方法 | |
CN105682656B (zh) | 调节法尼醇x受体的组合物和方法 | |
CN105579444B (zh) | 哌啶基吲哚衍生物和它们作为补体因子b抑制剂的用途 | |
WO2019201297A1 (zh) | 作为rho激酶抑制剂的苯并吡唑类化合物 | |
WO2022194221A1 (zh) | 呋喃稠环取代的戊二酰亚胺类化合物 | |
WO2023041055A1 (zh) | Kif18a抑制剂 | |
TW202132289A (zh) | 作為肝臟x受體促效劑之1,2,4-㗁二唑衍生物 | |
WO2022228544A1 (zh) | 异喹啉酮类化合物及其用途 | |
PT2475645E (pt) | 5-(3,4-dicloro-fenil)-n-(2-hidroxi-ciclo-hexil)-6- (2,2,2-trifluoro-etoxi)-nicotinamida e os seus sais como agentes para aumentar o colesterol hdl | |
WO2021249337A1 (zh) | 二甲基亚磺酰亚胺衍生物 | |
CN116507613A (zh) | 稳定转甲状腺蛋白四聚体的视黄醇结合蛋白4的双特异性拮抗剂及其制备和在治疗常见年龄相关合并症中的用途 | |
WO2003101983A1 (fr) | Derive tetrahydropyrane | |
US9212175B2 (en) | Pharmaceutical hypocholesterolemic compositions | |
WO2023078333A1 (zh) | 一种取代的苯丙酸衍生物及其用途一种取代的苯丙酸衍生物及其用途 | |
PT93045A (pt) | Processo para a preparacao de derivados de pirrolidina e de composicoes farmaceuticas que os contem | |
TWI746660B (zh) | 尿素衍生物及其用途 | |
JP3588363B2 (ja) | キノキサリンジオン類 | |
JP2009517483A (ja) | 一酸化窒素シンターゼの二量化の抑制剤としてのイミダゾール誘導体 | |
US10138240B2 (en) | Crystal of 5-hydroxy-4-(trifluoromethyl)pyrazolopyridine derivative | |
WO2024149261A1 (zh) | 补体因子b抑制剂 | |
JP2021523217A (ja) | ジアリールピラゾール化合物、該化合物を含む組成物およびその使用 | |
WO2023138592A1 (zh) | 一种嘧啶衍生物盐型晶型及制备方法 | |
WO2023036312A1 (zh) | 卤素取代的哒嗪酮类化合物及其应用 | |
US20200399224A1 (en) | Cyclopentaimidazolones for the treatment of cancer | |
WO2015080180A1 (ja) | 肺高血圧症治療剤 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 22889355 Country of ref document: EP Kind code of ref document: A1 |
|
WWE | Wipo information: entry into national phase |
Ref document number: 202490705 Country of ref document: EA Ref document number: AU2022381258 Country of ref document: AU |
|
WWE | Wipo information: entry into national phase |
Ref document number: 3235992 Country of ref document: CA |
|
REG | Reference to national code |
Ref country code: BR Ref legal event code: B01A Ref document number: 112024007416 Country of ref document: BR |
|
WWE | Wipo information: entry into national phase |
Ref document number: MX/A/2024/005304 Country of ref document: MX Ref document number: 2401002777 Country of ref document: TH |
|
ENP | Entry into the national phase |
Ref document number: 2022381258 Country of ref document: AU Date of ref document: 20221103 Kind code of ref document: A |
|
ENP | Entry into the national phase |
Ref document number: 20247017510 Country of ref document: KR Kind code of ref document: A |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2022889355 Country of ref document: EP |
|
ENP | Entry into the national phase |
Ref document number: 2022889355 Country of ref document: EP Effective date: 20240603 |